More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$390458708
EPS
-0.66
P/E ratio
--
Price to sales
8.19
Dividend yield
--
Beta
0.656411
Previous close
$9.19
Today's open
$9.26
Day's range
$8.79 - $9.43
52 week range
$5.03 - $13.35
show more
CEO
Kevin J. Knopp
Employees
172
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
41582397
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What 908 Devices (MASS) Said on Its Q3 Earnings Call
908 Devices NASDAQ: MASS reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally.
MarketBeat • Nov 10, 2026

908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

908 Devices: Solid Q3 Results
908 Devices delivered strong Q3 results with 35% year-over-year revenue growth, beating analyst estimates, and achieving a record 308 device placements. Management raised the low end of its 2026 revenue guidance range to $68.5 million while reducing losses from year ago levels. MASS improved its financial profile, generating $1.3 million in free cash flow year to date, and ended Q3 with $99.1 million cash and no debt.
Seeking Alpha • Nov 11, 2026

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026. "We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founde.
Business Wire • Nov 10, 2026

908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.15 per share a year ago.
Zacks Investment Research • Nov 10, 2026

908 Devices to Participate in the Stifel 2026 Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced that management will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 4:00 p.m. ET. A live webcast of the fireside chat will be available in the “Investors” section of the company's website at: www.908devices.c.
Business Wire • Nov 4, 2026

Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
Seeking Alpha • Oct 30, 2026

908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market open on Tuesday, November 10, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors”.
Business Wire • Oct 27, 2026

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
Business Wire • Sep 1, 2026

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
MarketBeat • Aug 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 908 Devices Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.